Table 3.

Patient characteristics and distribution of AI and CTCs in blood

Clinical parametersPatients totalNo. of patients with
AI*CTCs*
Diagnosis subgroup
    M069 (85.0%)31 (45.0%)49 (71.0%)
    M112 (15.0%)7 (58.5%)11 (92.0%)
    Total81 (100%)38 (47.0%)60 (74.0%)
Tumor stage
    pT1-pT240 (54.0%)16 (40.0%)27 (67.5%)
    pT3-pT434 (46.0%)18 (53.0%)28 (82.5%)
    Total74 (100%)34 (46.0%)55 (74.5%)
Gleason score
    ≤3+441 (54.0%)18 (44.0%)28 (68.5%)
    ≥4+335 (46.0%)18 (51.5%)29 (83.0%)
    Total76 (100%)36 (47.5%)57 (75.0%)
tPSA*%fPSA values
    Low risk22 (32.0%)11 (50.0%)17 (77.5%)
    High risk§47 (68.0%)22 (47.0%)34 (72.5%)
    Total69 (100%)33 (48.0%)51 (74.0%)
  • * Detection of one or more AI and CTCs was considered as positive.

  • tPSA*%fPSA, a combination of tPSA and %fPSA values.

  • Low-risk tPSA*%fPSA values: tPSA = 4-10 ng/mL plus fPSA>15% and tPSA>10 ng/mL plus fPSA>21%.

  • § High-risk tPSA*%fPSA values: tPSA = 4-10 ng/mL plus fPSA<15% and tPSA>10 ng/mL plus fPSA<10%.